LCP1 is a prognostic biomarker correlated with immune infiltrates in gastric cancer
LCP1 is a prognostic biomarker correlated with immune infiltrates in gastric cancer
复制标题
LCP1 是与胃癌免疫浸润相关的预后生物标志物
DOI：
10.3233/cbm-200006
复制
发表时间：
2021
影响因子：
3.1
通讯作者：
Zhengrong Li
中科院分区：
文献类型：
--
作者：
Qingwen Zeng;Leyan Li;Zongfeng Feng;Lianghua Luo;Jianbo Xiong;Zhigang Jie;Yi Cao;Zhengrong Li
背景：以前的研究已经确定LCP 1作为几种癌症的诊断和预后标志物。然而，LCP1在胃癌（GC）中的作用及其对肿瘤免疫浸润的影响仍不清楚。目的：探讨脂蛋白偶联蛋白1（LCP1）在胃癌中的作用及其对肿瘤免疫浸润的影响。方法：采用生物信息学分析和免疫组化方法，探讨LCP 1在胃癌组织中的表达及其与临床病理的关系。利用cBioportal数据库分析了GC中LCP 1的特征性遗传变异。此外，我们使用R软件、TIMER和TISIDB数据库评估了LCP 1表达与肿瘤浸润淋巴细胞（TIL）之间的相关性。最后，我们分析了LCP1可能参与的生物学功能及其可能调节的信号通路。结果：在这里，我们发现LCP1表达与胃癌患者的肿瘤侵袭性和不良预后显著相关。此外，结果表明，LCP1与TIL相关，包括免疫抑制细胞和免疫支持细胞，并且与GC中的各种免疫标记物集密切相关。GSEA分析表明，LCP1的表达在淋巴细胞形成和免疫反应中起重要作用。结论：LCP1可能是胃癌患者潜在的预后生物标志物和肿瘤免疫治疗的标志物。
BACKGROUND: Previous studies have identified LCP1 as a diagnostic and prognostic marker in several cancers. However, the role of LCP1 in gastric cancer (GC) and its effect on tumor immune infiltration remain unclear. OBJECTIVE: The aim was to explore the role of LCP1 in GC and its effect on tumor immune infiltration. METHODS: We explored the expression of LCP1 relative to clinicopathology in GC patients by bioinformatics analysis and immunohistochemistry. Using cBioportal database, we analyzed the characteristic genetic variations of LCP1 in GC. In addition, we evaluated the correlation between LCP1 expression and tumor-infiltrating lymphocytes (TILs) using R software, TIMER and TISIDB databases. Finally, we analyzed the biological functions in which LCP1 may participate and the signaling pathways it may regulate. RESULTS: Here, we showed that LCP1 expression is significantly correlated with tumor aggressiveness and poor prognosis in GC patients. Additionally, the results indicated that LCP1 was associated with TILs, including both immunosuppressive and immunosupportive cells, and was strongly correlated with various immune marker sets in GC. GSEA analysis demonstrated that LCP1 expression played an important role in lymphocyte formation and immune reaction. CONCLUSIONS: LCP1 may be a potential prognostic biomarker for GC patients and a marker for tumor immunotherapy.